Abstract
Juvenile idiopathic arthritis (JIA) is the most common autoimmune-autoinflammatory disease in childhood and affects approximately 1 in 1,000 children. Despite advances in diagnosis and treatment options, JIA remains a chronic condition for most affected children. Recent evidence suggests that disease control at onset may determine the tempo of subsequent disease course and long-term outcomes, and raises the concept of a therapeutic window of opportunity in patients with JIA. This underscores the importance of early aggressive treatment in patients with JIA. With the advent of novel biologic therapeutics, the repertoire of agents available for treatment of children with JIA has greatly increased. The present article will summarize recent developments in the medical treatment of children with JIA and will offer insights into emerging therapies.
Highlights
Juvenile idiopathic arthritis (JIA) is a chronic autoimmune– autoinflammatory disease of unknown etiology
Referred to as juvenile rheumatoid arthritis, the classification scheme for JIA was updated by the International League of Associations for Rheumatology in 2001 to reflect the unique nature of arthritis in childhood and to distinguish JIA from adult-onset rheumatoid arthritis (RA) [2]
Results indicated response rates and tolerability similar to those observed for etanercept and infliximab
Summary
Juvenile idiopathic arthritis (JIA) is a chronic autoimmune– autoinflammatory disease of unknown etiology. Beyond this pivotal randomized controlled trial, much of the literature reporting efficacy of etanercept in JIA is from uncontrolled open-label trials and case series involving patients with polyarticular and systemic JIA refractory to standard DMARD treatments such as nonsteroidal antiinflammatory drugs and methotrexate.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
